NCEL
NewcelX Ltd.
NASDAQ · Healthcare · Biotechnology · CH
$3.34
−0.30%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +75.3%
- EBIT
- +62.4%
- EPS
- —
- Free cash flow
- +70.0%
- Operating cash flow
- +70.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +38.4%
- EBIT
- +43.5%
- Net income
- —
- EPS
- +91.8%
- Free cash flow
- +35.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025